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https://doi.org/10.1016/j.stemcr.2019.01.007SUMMARYSatellite cells are responsible for skeletal muscle regeneration. Upon activation, they proliferate as transient amplifying myoblasts, most
of which fuse into regeneratingmyofibers. Despite their remarkable differentiation potential, these cells have limitedmigration capacity,
which curtails clinical use for widespread forms of muscular dystrophy. Conversely, skeletal muscle perivascular cells have less myogenic
potential but better migration capacity than satellite cells. Here we show that modulation of Notch and PDGF pathways, involved in
developmental specification of pericytes, induces perivascular cell features in adult mouse and human satellite cell-derived myoblasts.
DLL4 and PDGF-BB-treated cells express markers of perivascular cells and associate with endothelial networks while also upregulating
markers of satellite cell self-renewal. Moreover, treated cells acquire trans-endothelial migration ability while remaining capable of
engrafting skeletal muscle upon intramuscular transplantation. These results extend our understanding of muscle stem cell fate
plasticity and provide a druggable pathway with clinical relevance for muscle cell therapy.INTRODUCTION
Skeletal muscle homeostasis and regeneration rely on resi-
dent stem cells named satellite cells (SCs), which reside un-
derneath the basal lamina of the myofibers and express
the transcription factor Pax7. Upon injury, activated SCs
generate transient amplifying precursors called myoblasts,
which fuse to form multinucleated myofibers (Sambasivan
and Tajbakhsh, 2015). The regenerative capacity of SCs has
led to the development of cellular therapies to replace lost
or damaged muscle (Tedesco et al., 2010). Despite some
promising pre-clinical results and a good safety profile,
clinical trials based upon intramuscular myoblast trans-
plantation in patients with Duchenne muscular dystrophy
(DMD) have reported limited efficacy (Briggs and Morgan,
2013). This outcome has been ascribed to the poor survival
of myoblasts, their limited ability to migrate, and the host
immune reaction (Partridge, 2002), although this is still a
matter of active debate (Skuk and Tremblay, 2014). MoreThis is an open access article under the Crecently, local delivery of myoblasts to affected muscles
in oculopharyngeal muscular dystrophy patients has
shown encouraging results (Perie et al., 2014). Neverthe-
less, myoblasts are considered unsuitable for systemic
delivery, preventing their use for the treatment of patients
affected by severe myopathies with widespread muscle
involvement such as DMD.
Perivascular cells (pericytes in particular) support skeletal
muscle perfusion, development, and regeneration (Birbrair
and Delbono, 2015; Cappellari and Cossu, 2013; Murray
et al., 2017). Despite evidence in transgenic mice showing
that SCs (Relaix and Zammit, 2012) and not pericytes (Gui-
maraes-Camboa et al., 2017) are required formuscle regener-
ation, there are reports indicating that pericyte-derived cells
can also contribute to skeletal myogenesis, including SC
generation and maintenance (Dellavalle et al., 2011, 2007;
Kostallari et al., 2015; Sacchetti et al., 2016; Tedesco et al.,
2011). Discrepancies among reports may be due to the use
of different markers to identify interstitial/perivascular cellsStem Cell Reports j Vol. 12 j 1–13 j March 5, 2019 j ª 2019 1
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progenitors derived from skeletal muscle perivascular cells
(mainly mesoangioblasts, deriving from in vitro expansion
of a subset of muscle pericytes) resulted in the colonization
of skeletal muscle tissue downstream of the injection site
and subsequent amelioration of different animal models
of muscular dystrophy (Benedetti et al., 2013). Moreover, a
recent first-in-human phase I/IIa clinical trial based on
intra-arterial delivery of human leukocyte antigen-matched
mesoangioblasts inDMD children has established the safety
and feasibility of this procedure (Cossu et al., 2015). While
they may be an important source for transplantation, the
skeletal myogenic and self-renewing potential of perivascu-
lar cells is suboptimal compared with SCs, and their prelim-
inary clinical investigation indicates that further optimiza-
tion will be needed for muscle cell therapy (Cossu et al.,
2015). Therefore, a muscle stem cell harboring SCmyogenic
and self-renewing capacity combined with the migration
ability of perivascular cells could be ideal for muscle cell
therapies.
Several groups have shown that the Notch signaling
pathway, a key regulator of myogenesis and pericyte
function, can alter the behavior of myogenic precursors
(Mourikis and Tajbakhsh, 2014; Sainson and Harris,
2008). The Notch ligand delta ligand 1 (DLL1) promotes
SC quiescence (Baghdadi et al., 2018) and increases engraft-
ment of canine muscle cells (Parker et al., 2012), whereas
DLL4 regulates mouse SC self-renewal (Low et al., 2018;
Verma et al., 2018); however, DLL1 and DLL4 alone did
not significantly improve engraftment of mouse and hu-
man SCs (Sakai et al., 2017). Conversely, Notch depletion
leads to SC exhaustion, impairment of muscle regenera-
tion, and reduced engraftment of mesoangioblasts (Bjorn-
son et al., 2012; Mourikis et al., 2012; Quattrocelli et al.,
2014; Schuster-Gossler et al., 2007; Vasyutina et al., 2007).
Platelet-derived growth factor (PDGF) signaling also has
important roles in regulating smooth and skeletal muscle
cell fate. The PDGF signaling pathway comprises the two
receptors a (PDGFR-A) and b (PDGFR-B), which bind to li-
gands PDGF-A/-B/-C/-D as homo- or hetero-dimers (Lu
and Li, 2017). PDGF-B is expressed in both SC and pericytes
(Pinol-Jurado et al., 2017), affecting their proliferation,
migration, recruitment, and fate (Lindahl et al., 1997; Pal-
lafacchina et al., 2010; Sugg et al., 2017; Yablonka-Reuveni
et al., 1990). In addition, PDGF-BB is upregulated in dystro-
phic myofibers and attracts myoblasts (Pinol-Jurado et al.,
2017); with a similar mechanism, endothelial cells recruit
mural cells via PDGF-BB (Betsholtz, 2004). Importantly,
Notch induces PDGFR-B, and this combined signaling di-
rects vascular smooth muscle cell fate choice (Jin et al.,
2008).
Previously we reported that mouse embryonic myoblasts
undergo a fate switch toward the perivascular lineage2 Stem Cell Reports j Vol. 12 j 1–13 j March 5, 2019following stimulation with DLL4 and PDGF-BB (Cappellari
et al., 2013). Although this prior study suggests bidirec-
tional fate plasticity between SCs and pericytes, there is
currently no evidence indicating that a similar phenome-
non is conserved in adult myogenic progenitors. Here, we
provide evidence that adult skeletal muscle SCs gain peri-
cyte properties in response to DLL4 and PDGF-BB treat-
ment, while also re-acquiring a stemness signature.RESULTS
DLL4 and PDGF-BB Treatment Induces Reversible
Changes in Morphology, Proliferation, and
Differentiation of Adult Murine Satellite Cell-Derived
Myoblasts
To determine whether adult SCs respond to the activation
of Notch and PDGF pathways, primary SC-derived
myoblast cultures (hereafter referred to as SCs) were estab-
lished from wild-type mice (Figure S1A) and cultured on
collagen-coated dishes (to aid attachment) or seeded on
DLL4-coated dishes supplemented daily with PDGF-BB. Af-
ter 1 week of treatment, the morphology of the treated SCs
was compared with untreated control SCs, revealing a
change from a round to amore elongatedmorphology (Fig-
ures 1A and 1B).
Notch activity controls SC activation, proliferation, and
quiescence (Bjornson et al., 2012; Brohl et al., 2012; Mour-
ikis et al., 2012). Consistent with these reports, we observed
reduced proliferation of SCs exposed to the treatment (Fig-
ure 1C). This effect was reverted by discontinuation of the
treatment. Interestingly, reduced cell proliferation was also
observedwhen the treatmentwas commenced on cells that
were previously expanded for 2 weeks in control condi-
tions, indicating that the responsiveness to treatment was
not impaired with extensive culture (Figures 1D–1F). Spe-
cifically, proliferation was analyzed by functional 5-ethy-
nyl-20-deoxyuridine (EdU) incorporation assay and nuclear
Ki67 immunofluorescence staining. Both assays showed a
decrease in proliferation from control to treated SCs:
28.19% vs 10.94% EdU incorporation (p = 0.021, N = 3)
and 45.60% vs 20.44% Ki67 positivity (p = 0.047, N = 3).
Notch activation inhibits myogenesis in vitro both in em-
bryonic myoblasts and adult SCs (Conboy and Rando,
2002; Kopan et al., 1994; Mourikis and Tajbakhsh, 2014).
To investigate if this mechanism is triggered upon treat-
ment with DLL4 and PDGF-BB, cells were differentiated
into skeletal myotubes and immunoassayed for myosin
heavy chain (MyHC) (Figures 1G and 1H). A significant
reduction in myogenic differentiation upon treatment
was observed, from 71.5% to 37.9% (p = 0.031, N = 3
mice in 4 experiments), reflecting the role of Notch
signaling in inhibiting myogenesis. This differentiation
Figure 1. Morphology, Proliferation, and Differentiation of DLL4 and PDGF-BB-Treated SCs
(A) Phase contrast images of untreated and DLL4 and PDGF-BB-treated SCs isolated from CD1 mice.
(B) Graph quantifies circularity ratio, where 1 = circle and 0 = line (n = 3).
(C) Proliferation curves of untreated and treated SCs over time (n = 3). Box highlights treatment switch.
(D–F) Immunofluorescence analysis of SCs isolated from TN-APcre:TdTomato mice expanded for 2 weeks prior to treatment, or maintained
in untreated conditions. Cells pulsed for 2 h with EdU and co-immunostained with Ki67 (arrowheads: nuclear signal) (N = 3) (D). Quantified
in (E and F).
(G) Immunofluorescence images of untreated and treated SCs differentiated into myotubes in low mitogen medium for 4 days and
immunostained for myosin heavy chain (MyHC) and Hoechst (N = 3 mice and 4 experiments).
(H) Untreated and treated SCs differentiated in low mitogen medium supplemented with 660 ng/mL of the g-secretase inhibitor L-685,458
to inhibit Notch signaling (N = 3).
Data: means ± SEM. Statistical significance based on paired (E and F) or unpaired (G and H) Student’s t test; *p < 0.05; n.s., not significant.
Scale bars, 25 mm (D) and 100 mm (A, G, and H).
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with the g-secretase inhibitor L685,458 (N = 3), confirming
the Notch dependency of this phenomenon (Figures 1G
and 1H).
DLL4 and PDGF-BB Treatment Induces Transcription
of Perivascular and SC Genes
To understand the mechanism behind the observed prolif-
eration and differentiation changes, a series of real-time
qPCR analyses was performed to investigate the variation
in the gene expression profile of SCs upon DLL4 and
PDGF-BB treatment. Preliminary experiments performed
with SCs isolated with the pre-plating methodology fromCD1 mice (Figure S1A) suggested that a number of tran-
scripts associated with Notch and PDGF pathways, as well
as myogenic and smooth muscle programs, responded to
treatment (Figure S1B).
To ensure that the observed gene expression profile was
directly elicited by DLL4 and PDGF-BB on bona fide SCs
and not on a possible minority of contaminating cells, we
used SCs isolated from Tg:Pax7-nGFP mice (Sambasivan
et al., 2009) (Figure 2A). Analysis of the expression of
Notch1, the main receptor for DLL4, and of Pdgfrb, showed
significant transcriptional upregulation, confirming that
treatment with DLL4 and PDGF-BB activated the expected
signaling pathways (p = 0.038 and p = 0.017, respectively,Stem Cell Reports j Vol. 12 j 1–13 j March 5, 2019 3
Figure 2. Gene Expression Analyses of Treated SCs via Real-Time qPCR and Immunofluorescence
(A) Histogram view of the FACS purification of PAX7-GFP+ SCs and resulting pure population in phase contrast and GFP images.
(B) Real-time qPCR analysis of untreated (black bars) and DLL4 and PDGF-BB-treated (green bars) PAX7-GFP+ SCs. Graphs show fold change
to control conditions, statistical significance based on DCt (N = 4).
(C) Left panel: PAX7-GFP+ SCs cultured in control (untreated) or DLL4 and PDGF-BB conditions and immunostained with MYOD (red) and
PAX7 (green) antibodies. Right graph quantifying the relative percentages of PAX7/MYOD +/ cells in each condition (N = 3).
Data: means ± SEM. Statistical significance based on paired Student’s t tests (B) or two-way ANOVA with Bonferroni’s multiple comparison
(C). *p% 0.05, **p% 0.01, ****p% 0.0001, n.s., not significant. Scale bars, 50 mm (A and C). See also Figure S1.
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of Notch targets Hes1 (p = 0.028) and Hey1 (p = 0.022).
Notch induces Pdgfrb expression in vascular smooth
muscle cells (Jin et al., 2008), which may explain the
remarkable induction of Pdgfrb. Interestingly, the treat-
ment induced genes usually more expressed in smooth
muscle cells and pericytes, including Ng2 (p = 0.024) and
Sm22 (p = 0.003), while also increasing expression of the
SC marker Pax7 (p = 0.032). Finally, quantification of alka-
line phosphatase (AP) activity, which is associated with
myogenic pericytes (Dellavalle et al., 2011), suggested upre-
gulation in treated cells (Figure S1C).
We then measured PAX7 and MYOD proteins in SCs
treated with DLL4 and PDGF-BB (Figure 2C, N = 3). PAX7
marks quiescent, self-renewing, and primed SCs, whereas
MYOD is associated with committed progenitors (i.e., myo-
blasts) (Zammit et al., 2004). Similar towhat was observed at4 Stem Cell Reports j Vol. 12 j 1–13 j March 5, 2019the mRNA level, the percentage of PAX7+/MYOD– cells
increased from2.97% in untreated cells to 42.47% in treated
cells (p < 0.0001). Conversely, the percentage of PAX7+/
MYOD+ SCs decreased with DLL4 and PDGF-BB treatment,
from73.90% to 43.79% (p < 0.0001), suggesting that treated
cells retained a more ‘‘stem-like’’ state.
For this treatment to be applicable to human cells,
response needs to be maintained following expansion in
culture. To test this, we assessed whether SCs were respon-
sive to treatment when expanded for 2 weeks prior to
treatment, revealing an increase in the proportion of
PAX7+/MYOD– SCs (p = 0.001, N = 4; Figure S1D).
Finally, we observed that the morphological changes eli-
cited in treated SCs correlated to an ability of the cells to
adhere directly to plastic, rather than requiring collagen
coating. To confirm that the effect of DLL4 and PDGF-BB
treatment was independent of collagen coating, SCs from
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and treatment conditions on collagen-coated or uncoated
culture dishes: proliferation kinetics andmRNA expression
analyses revealed that the effect was independent of
coating (Figures S1E and S1F; N = 3). Taken together, these
results show that DLL4 and PDGF-BB treatment induces a
perivascular-like gene expression profile in SCs while
maintaining or inducing a signature associated with their
self-renewal.
DLL4 and PDGF-BB-Treated SCs Gain Properties of
Perivascular Cells
We next aimed to test whether the expression of perivascu-
lar markers on SC treatment with DLL4 and PDGF-BB was
also accompanied by functional pericyte properties. Peri-
cytes contribute to the stabilization of endothelial net-
works in hydrogels on vascular endothelial growth factor
(VEGF) stimulation (Cappellari et al., 2013). To determine
whether DLL4 and PDGF-BB treatment conferred this func-
tional property to SCs, treated cells were co-cultured with
human umbilical vein endothelial cells (HUVECs) in
Matrigel and stimulated with VEGF. To allow cell tracing
in co-culture, SCs were isolated from Tg:CAG-EGFP mice,
which ubiquitously express the green fluorescent protein
(GFP) (Okabe et al., 1997). After 24 h in culture, endothelial
networks showed limited branching and partial disaggrega-
tion when cultured alone or with untreated SCs; however,
networks showed increased branching and stability when
co-cultured with SCs exposed to DLL4 and PDGF-BB, simi-
larly to control skeletal muscle pericytes (Figures 3A–3D).
A characteristic of pericyte-derived mesoangioblasts is
their ability tomigrate outside blood vessels upon intravas-
cular delivery in models of muscular dystrophy (e.g., Gian-
notta et al., 2014; Tedesco et al., 2011). To investigate
whether DLL4 and PDGF-BB-treated SCs acquired this
property, we first performed a transwell assay on an H5V
murine endothelial cell monolayer andmeasured the num-
ber of control or treated SCs that migrated through the
endothelial layer after 6 h. Notably, treated cells had about
a 3-fold increase in migration ability compared with un-
treated SCs (p < 0.01, N = 3; Figure 3E). Subcutaneously in-
jected DLL4 and PDGF-BB-treated SCs transplanted into
Matrigel plugs also appeared to migrate more toward
CD31/PECAM+ host blood vessels, suggesting a response
to chemotactic signals from the native endothelium (Fig-
ure S2, N = 2).
Proof-of-principle in vivo testing was then performed to
determine whether improved migration through an endo-
thelial monolayer in vitro resulted in SCs with the capacity
to cross an actual blood vessel wall. To easily visualize cells,
they were transduced with a lentivirus carrying a nuclear
LacZ cDNA (nLacZ), which enables b-galactosidase
(b-GAL)-mediated identification of donor cells with theX-gal reaction. A total of 106 control or treated GFP+/
nLacZ+ SCs were injected into the femoral arteries of
dystrophic immunodeficient a-sarcoglycan-null/scid/
beige mice (Sgcatm1KcamPrkdcscidLystbg, Sgca-null/scid/beige
hereafter; Tedesco et al., 2012) as reported previously (Gerli
et al., 2014). This strain was chosen as it displays a more
severe dystrophic phenotype compared with the mdx
mouse and does not have revertant fibers. Prior to trans-
plantation cells were stained with X-gal to determine the
efficiency of transduction (84% X-gal+). Three weeks after
transplantation, scattered GFP+/X-gal+ donor-derived
nuclei were observed in muscles downstream of the injec-
tion site in limbs transplanted with DLL4 and PDGF-BB-
treated SCs, with muscles receiving untreated SCs showing
little to no signal (Figure 4A). The relatively low frequency
of the eventmade it difficult to quantify with conventional
methods (e.g., nuclei/section); however, the average X-gal+
area in themedial aspect of the hindlimbmuscles increased
from 0.02 mm2 to 0.1 mm2 (p = 0.028, N = 4, Figure 4A),
suggesting an acquired ability of treated SCs to cross the
blood vessel wall upon intra-arterial delivery. X-gal staining
of filter organs (i.e., liver, spleen, kidneys, and lungs)
showed no donor nuclei in mice receiving control or
DLL4 and PDGF-BB-treated SCs intra-arterially (data not
shown). These experiments show that DLL4 and PDGF-
BB treatment induces perivascular properties to SCs such
as endothelial branch stabilization, as well as improved
migration in vitro and in vivo.
DLL4 and PDGF-BB-Treated Mouse SCs Engraft
Skeletal Muscle following Intramuscular
Transplantation
To investigate if the increased migration resulted in
improved in vivo engraftment while retaining their
myogenic memory, 1 3 106 GFP+/b-GAL+ SCs were trans-
planted intramuscularly into the tibialis anterior (TA) mus-
cle of Sgca-null/scid/beigemice (N = 5, Figures 4B–4F). Three
weeks after transplantation, explanted muscles were cryo-
sectioned and co-stained for X-gal and a-sarcoglycan
(SGCA) to detect donor-derived cells and their contribution
tohost tissues. This analysis revealed that thenumber of en-
grafted cells significantly increased with DLL4 and PDGF-
BB treatment (p = 0.047, Figure 4B). Although TA muscles
engrafted with treated SCs appeared to have more cells per
section and a greater migration throughout the muscle
than control SCs (Figure 4C), the percentage of X-gal+
nuclei located within myofibers (i.e., donor myonuclei)
was unchanged with the treatment (Figure 4D). Finally, a
similar number of SGCA+myofibers was also observed (Fig-
ures 4E and 4F), indicating full differentiation capacity of
treated SCs. In parallel, tumor formation assays based on
subcutaneous injection of 2 3 106 treated SCs were per-
formed to assess safety of the signalingmanipulation. AfterStem Cell Reports j Vol. 12 j 1–13 j March 5, 2019 5
Figure 3. In Vitro Assessment of Endothelial Network Association and Migration Properties of DLL4 and PDGF-BB-Treated SCs
(A) Representative images from endothelial network formation assays at 24 h with GFP+ untreated or DLL4 and PDGF-BB-treated SCs
and control yellow fluorescent protein (YFP)+ primary muscle pericytes (technical control, from Tg:TN-AP-CreERT2:R26R-EYFP mice)
stimulated with VEGF in the presence of HUVECs.
(B) Graph depicts quantification of network branches per mm2 at 24 h in the same experimental groups shown in (A) (N = 4).
(C and D) Graph quantifies GFP+ SCs and YFP+ pericytes associated with the network per high-power field (HPF = 1.5 mm2) over time (N = 4);
representative image of treated cells at 72 h shown in (D).
(E) Images of the lower side of transwell membranes from GFP+ untreated or treated SCs and control pericyte-derived mesoangioblasts
(MABs) seeded on a monolayer of H5V murine endothelial cells. Graph quantifies the average number of cells/mm2 that migrated through
the endothelial layer after 6 h (N = 3).
Means ± SEM; statistical significance based on one-way ANOVA with Dunnett’s multiple comparison test (B and C) or paired t test (E);
*p < 0.05, **p% 0.01. Scale bars, 100 mm.
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Figure 4. In Vivo Assessment of Migration and Engraftment of DLL4 and PDGF-BB-Treated SCs
(A) In vivo analysis of limb muscles from Sgca-null/scid/beigemice intra-arterially transplanted with 106 GFP+/b-GAL+ control or DLL4 and
PDGF-BB-treated SCs after 3 weeks. Upper panel: exposure to X-gal revealed engraftment of b-GAL+ donor cells (blue; arrowhead) in the
knee region and lower limb muscles of mice transplanted with DLL4 and PDGF-BB-treated SCs. Lower panel: assessment of X-gal in the
gastrocnemius muscle of mice transplanted with treated SCs, revealing nuclear localization of b-GAL in a GFP+ myofiber (arrowheads).
Graph quantifies the area of X-gal+ signal in muscles intra-arterially transplanted with treated or untreated SCs (lateral view of knee
region) normalized to the volume of cell suspension delivered (N = 4).
(B) Quantification of transplanted cells that engrafted intramuscularly injected TA muscles (N = 5).
(C) Distribution across muscle length of X-gal+ nuclei per section of TA muscles transplanted with treated and untreated SCs (N = 5).
(D) Quantification of the localization (i.e., inside or outside myofibers) of X-gal+, treated/untreated, donor-derived nuclei in transplanted
muscles (N = 5).
(E) Immunofluorescence panel showing a representative Scga-null/scid/beige muscle transplanted with 106 GFP+/nLacZ+ DLL4 and PDGF-
BB-treated SCs intramuscularly 3 weeks before explant. SGCA (red) and X-gal (violet): donor-derived fibers and nuclei, respectively.
LAMININ (green) and Hoechst (blue): extracellular matrix and nuclei, respectively.
(F) Quantification of the experiment in (E) showing the average number of donor-derived fibers from three mice.
Data: means ± SEM. Statistical significance based on unpaired Welch’s t test. *p < 0.05; n.s., not significant. Scale bars, 2 mm (A, left
panel), 250 mm (A, middle panel), 50 mm (A, right panel), and 50 mm (E).
Please cite this article in press as: Gerli et al., Combined Notch and PDGF Signaling Enhances Migration and Expression of Stem Cell
Markers while Inducing Perivascular Cell Features..., Stem Cell Reports (2019), https://doi.org/10.1016/j.stemcr.2019.01.007a minimum 2-month follow-up, no tumors were seen (N =
5 mice), indicating that the treatment did not result in
oncogenic transformation of treated cells. These data
showthat, upon treatmentwithDLL4andPDGF-BB,mouse
SC-derived myoblasts have improved engraftment in host
skeletal muscle than untreated cells, althoughwith compa-
rable contribution to myofiber repair/regeneration.
Human SC-Derived Myoblasts Respond to DLL4 and
PDGF-BB Stimulation
Translation of this strategy into future pre-clinical studies
requires evidence that the mechanism is conserved also
in human SC-derived myoblasts (hereafter referred to as
HuSCs). To this aim, primary human muscle biopsy-
derived SCs fromfive individuals (HuSCs 1–5) were isolated
and purified by fluorescence-activated cell sorting (FACS)
for CD56 positivity, which marks HuSCs (Boldrin et al.,
2010). Purified SCswere expanded and treatedwith humanDLL4 and PDGF-BB for 7 days or expanded in control con-
ditions. Proliferation analyses (Figures 5A–5C) revealed
that, unlike murine SCs, the percentage of EdU+ cells was
unaffected by DLL4 and PDGF-BB treatment (Figure 5B).
The exception to this was donor no. 4, where a
significant increase was observed (p = 0.002). The percent-
age of Ki67+ cells was assessed in three HuSC preparations
to confirm EdU analyses, which, although variable be-
tween preparations, was unaffected when results were
averaged (Figure 5C).
Analysis of transcriptional changes elicited by DLL4 and
PDGF-BB treatment showed activation of Notch signaling
via increased HEY1 (HuSC3 p = 0.006, HuSC5 p = 0.028)
and HES1 (HuSC3 p > 0.0001, HUSC5 p = 0.003), although
differences in expression levels were observed between the
preparations assessed (Figure 5D). A trend in the increase of
PDGFRB transcripts was also observed, although not statis-
tically significant. As with murine SCs, myogenic markersStem Cell Reports j Vol. 12 j 1–13 j March 5, 2019 7
(legend on next page)
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NIN (HuSC5 p = 0.007) were decreased, whereas the peri-
cyte marker TNAP was increased (p < 0.0001). This corre-
lated with an increase in AP enzymatic activity
(Figure 5E). PAX7 expression did not increase significantly
with treatment, although all samples expressed very low
baseline levels, likely due to cell expansion in culture, or
distinct regulation of this gene in the human compared
with mouse (Figure 5D).
We then tested HuSC differentiation in response to DLL4
andPDGF-BB treatment. To determinewhether any changes
were due to Notch, cells were differentiated in low mitogen
medium for 4 days in the presence or absence of g-secretase
inhibitor (Figure 5F). In all preparations assessed, DLL4 and
PDGF-BB treatment reduced myogenic differentiation,
whichwas rescuedby inhibitingNotch signaling (Figure 5F).
To assess whether transcriptional changes induced by
DLL4 and PDGF-BB treatment had functional consequences
in HuSCs, transmigration ability was assessed via transwell
assay on a monolayer of HUVECs (Figure 5G, N = 3). After
8 h, treated cells showed an average 2-fold overall increase
in migration capacity, from 15.02 to 32.54 cells/mm2 (p =
0.008), although some variability was observed among
the lines assessed (e.g., p = 0.144 for HuSC3 and p = 0.046
for HuSC5). Taken together, these results indicate that
DLL4 and PDGF-BB induce cell fate changes and improve
migration also in HuSCs, laying the foundation for further
studies on this strategy for human muscle cell therapy.DISCUSSION
In this work, we hypothesized that cell fate determinants
involved in smooth and skeletal muscle lineage determina-Figure 5. Effect of DLL4 and PDGF-BB Treatment on Human SC-De
(A) Representative images of CD56+ FACS-purified human SC-deriv
control conditions (upper panel) or treated with DLL4 and PDGF-BB (
co-immunostained with Ki67 (red).
(B) Quantification of the percentage of EdU+ cells (N = 5).
(C) Quantification of Ki67+ cells (N = 3).
(D) Real-time qPCR analysis of myogenic (PAX7,MYOD, andMYOGENIN)
and HEY1) genes in response to DLL4 and PDGF-BB treatment in Hu
conditions, statistical significance based on DCt.
(E) Phase contrast images of AP enzymatic activity (violet) and Hoec
(F) Differentiation of HuSCs in response to DLL4 and PDGF-BB treatm
conditions for 1 week and induced to differentiate for 4 days in the pre
and graphs quantify the percentage of MyHC+ cells (N = 4).
(G) Representative images of the lower chambers of transwell assa
mesoangioblasts (MABs; technical control) were seeded for 8 h on HU
condition. N = 3; means ± SEM.
Statistical significance based on paired Student’s t test (B, C and ce
data in G) or one-way ANOVA with Tukey’s multiple comparison (F). *
significant. Scale bars, 50 mm (A), 75 mm (F), and 100 mm (E and G).tion in the embryo may exert a similar effect also on adult
SCs, and that their modulation could be exploited to
improve skeletal muscle cell therapies. Direct lineage re-
programming (also known as trans-differentiation) is the
conversion of one functional cell type to another fate
without an intermediate pluripotent step (Xu et al.,
2015). Here, we show that a phenomenon resembling
reversible lineage reprogramming takes place in adult SCs
in response to DLL4 and PDGF-BB stimulation. Adult SC-
derived myoblasts treated with DLL4 and PDGF-BB in-
crease expression of perivascular genes. At variance with
their embryonic counterpart (Cappellari et al., 2013), adult
SCs acquired also an expression profile suggestive of self-re-
newing SCs (i.e., high PAX7 and lowMYOD). However, the
co-expression of SC and perivascularmarkers indicates that
the treatment does not trigger a complete trans-
differentiation, but rather a stimulus-dependent reprog-
ramming into a hybrid cell type. Our isolation procedures
(FACS purification using PAX7-GFP for murine cells and
CD56 for their human counterpart) minimize the possibil-
ity that the observations are due to contaminating cells.
Similar to bona fide pericytes, treated SCs become associ-
ated with endothelial networks (Armulik et al., 2005).
Notably, transwell assays and in vivo experiments showed
improved ability of treated SCs to cross endothelial barriers,
suggesting acquisition of a similarmachinery that pericyte-
derived mesoangioblasts might use to cross the blood
vessel wall (Giannotta et al., 2014).
Manipulating Notch signaling affects SC differentiation
and transplantation ability. Recently, it was shown that
while Jagged1, DLL1, or DLL4 alone can maintain a stem-
like phenotype in SCs grown ex vivo, this does not correlate
with an increased efficiency to generate myofibers upon
transplantation (Sakai et al., 2017). Interestingly, ourrived Myoblasts
ed myoblasts from two individuals (HuSC 3 and 5) expanded in
lower panel) for 1 week, then pulsed for 2 h with EdU (green) and
, perivascular (PDGFRB, TNAP, and CD146) and Notch signaling (HES1
SC 3 and 5 (n = 3 per line). Graphs show fold change to control
hst (blue) in untreated and treated HuSCs.
ent and Notch inhibition. Cells expanded in control or treatment
sence or absence of L-685,458. Pictures representatives from HuSC1,
ys. Untreated/treated HuSCs and human muscle pericyte-derived
VECs. Right graph: number of 6-CFDA+ migrated cell/mm2 in each
ll-line-specific data in G), unpaired Student’s t test (D and pooled
p < 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001; n.s., not
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DLL4 induces perivascular features in SCs and increases
their engraftment into host skeletal muscle, albeit
with a similar contribution tomyofibers.We hypothesize
that thismight be due to increasedmigration throughout
the host muscle resulting in fusion of more donor
cells with the same myofibers. Hence, this migration-
enhancing strategy preserves the overall SC engraftment
and differentiation potential without altering their
safety profile, as shown by lack of oncogenic transforma-
tion in transplantation experiments and tumorigenesis
assays.
It is thought-provoking to speculate that satellite and
perivascular cells might retain bidirectional plasticity in
adulthood due to a residual developmental memory from
a common precursor. It has been shown that skeletal and
vascular smooth muscle cells have a common PAX3+ pro-
genitor in the dermomyotome (Esner et al., 2006; Goupille
et al., 2011; Lagha et al., 2009). At later stages of develop-
ment, it has been shown that embryonic myoblasts and
skeletal muscle pericytes maintain the ability to trans-
differentiate toward a smooth or skeletal muscle fate, in
response to DLL4, PDGF, and Noggin signaling, respec-
tively (Cappellari and Cossu, 2013). Although experiments
in mice challenge the model of endogenous pericytes as
tissue-resident progenitors (Guimaraes-Camboa et al.,
2017), there is evidence that human skeletal myogenic pro-
genitors are associated with blood vessel walls in vivo in
perivascular locations typical of mural cells/pericytes or
adventitial cells of muscular veins (Dellavalle et al., 2007;
Sacchetti et al., 2016). This population has been hypothe-
sized to represent either a subset of myogenic progenitors
recruited to separate niches based on proximity (i.e., satel-
lite vs vascular niche), or, alternatively, to be a class of pro-
genitors upstream of SCs. Both models would fit with our
data, with DLL4 and PDGF-BB treatment either mimicking
in vitro what hypothesized by the first model or bringing
the cells back to their primitive nature, as per the second
model. Although ex vivo culture is a key procedure used
in this study, previous in vivo evidence in the developing
embryo underpins this skeletal muscle-vascular crosstalk
in adult SCs. Specifically, we demonstrated that SCs are
responsive to DLL4 and PDGF-BB treatment irrespective
of mouse strain (CD57BL/6 and CD1), isolation procedure
(pre-plating or PAX7-GFP sorting), tissue culture substrate,
timing of treatment (i.e., immediately upon isolation or
following expansion) or species (mouse and human).
Future applications of this strategy include its extension
to pluripotent cell-derived myogenic cells, which we and
others are developing as a promising tool for regenerative
medicine (Loperfido et al., 2015). Taken together, our
data indicate that SC plasticity toward the perivascular
lineage is conserved in adulthood and opens the possibility10 Stem Cell Reports j Vol. 12 j 1–13 j March 5, 2019to exploit this phenomenon to generate clinically relevant
stem cell populations for future cell therapies of muscle
disorders.EXPERIMENTAL PROCEDURES
Animals
Mouse strains used in this study: Tg:Pax7-nGFP F1:C57BL/6:DBA2
expressing nuclear-localized EGFP in Pax7-expressing cells (Sam-
basivan et al., 2009); Tg:TN-AP-CreERT2 (Dellavalle et al., 2011);
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze, a Td:Tomato reporter in
Cre-expressing cells (Madisen et al., 2010) hereafter referred to
as Td:Tomato; R26R-EYFP, a reporter expressing cytoplasmic YFP
in Cre-expressing cells (Srinivas et al., 2001); Tg:CAG-EGFP mice
expressing ubiquitous GFP (Okabe et al., 1997); CD1 and Sgca-
null/scid/beige mice (Sgcatm1KcamPrkdcscidLystbg; Tedesco et al.,
2012). Housing of all mice (except Tg:Pax7-nGFP) and all experi-
mental procedures were performed in accordance with British law
under the provisions of the Animals (Scientific Procedures) Act
1986, as approved by the University College London Ethical Re-
view Process committees and under UK Home Office Project
Licence 70/8566. Surgery was performed under isoflurane anes-
thesia and every effort made to minimize pain and suffering,
including use of analgesia. Tg:Pax7-nGFP mice were bred at the
Institut Pasteur (Paris, France), in compliance with European
legislation and under the approval of the institutional ethical
committee.Cell Isolation, Culture and Assays
Primary murine SCs and pericytes were isolated from dissected
adult skeletal muscles and cultured as detailed in Supplemental
Experimental Procedures. HuSCs were obtained from the MRC
Neuromuscular Center Biobank (UCL, London, UK; Research
Ethics Committee reference no. 06/Q0406/33). Human cell work
was conducted under the approval of the NHSHealth Research Au-
thority Research Ethics Committee reference no. 13/LO/1826;
IRAS project ID no. 141100. Additional details, including full
information on cell culture, purification and protocols used in
morphological, proliferation, differentiation, network formation,
migration, and transplantation assays are available in Supple-
mental Experimental Procedures.DLL4 and PDGF-BB Treatment
Murine recombinant DLL4 (R&D Systems; 1389-D4-050) was
resuspended to a concentration 10 mg/mL in sterile PBS con-
taining 1% wt/vol BSA. Flasks were coated with DLL4 at 37C
for 45 min before seeding cells. Cultures were supplemented
daily with 50 ng/mL of recombinant PDGF-BB (Sigma;
P4056) resuspended in 0.1% BSA/4 mM HCl/PBS. For human
myoblast treatment, recombinant human DLL4 (R&D Systems;
1506- D4-050) and human PDGF-BB (R&D Systems; 220-BB-
050) were dissolved and treated as murine proteins to final
concentrations of 10 mg/mL and 100 ng/mL, respectively. Cells
were assessed after at least 7 days of treatment, by which time
they had been passaged at least once on fresh DLL4-coated
plates.
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Cells and tissue sections were fixed in 4% paraformaldehyde, per-
meabilized using 0.1% Triton and 1% BSA PBS and blocked in 10%
donkey or goat serum in PBS for 60 min. Samples were then
incubated overnight at 4Cwith the following primary antibodies:
mouse anti-MyHC (DSHB MF20, 1:10), mouse anti-CD31/PECAM
(DSHB P2B1, 1:2), mouse anti-PAX7 (DSHB, 1:1), rabbit anti-Ki67
(Leica NCL-Ki67p, 1:1,000), mouse anti-a-sarcoglycan (anti-
SGCA, Novocastra NCL-a-SARC, 1:150 and Abcam AB49451,
1:150), rabbit anti-SGCA (Abcam EPR14773, 1:1,000 on unfixed
sections) rabbit anti-LAMININ (Abcam AB11575, 1:300), rabbit
anti-MYOD (Santa Cruz Biotechnology M-318, 1:300). Samples
were then incubated with fluorescently-conjugated donkey or
goat secondary antibodies (Molecular Probes, Alexa Fluor series,
1:500). Hoechst 33342 (Fluka B2261) was used to counterstain
nuclei. AP and X-gal staining were performed by incubating cells
at room temperature or 37C, respectively, until a colorimetric
change was observed (Roche NBT/BCIP-11681451001 and Sigma
3117073001).
Gene Expression Analyses
RNA extraction was performed with RNeasy kits (QIAGEN), yield
and purity assessed with a Nanodrop spectrophotometer and
reverse transcribed into cDNA with the Improm-II Reverse Tran-
scription System kit (Promega; A3800). Relative gene expression
values were measured by real-time qPCR using the SYBR Green
Real-Time Master Mix (Promega; A600A) on a Bio-Rad CFX96
machine. Real-time qPCRs were performed in triplicate on samples
from at least three independent experiments. Gapdh and RPLPO
were used as housekeeping genes for murine and human experi-
ments, respectively. Data presented as means ± SEM of the fold
change, normalized to control SCs. Significance was assessed on
the delta Ct values using Student’s t test assuming two-tailed distri-
bution and equal variances. Sequences of primers available in Sup-
plemental Experimental Procedures.
Statistics
Statistical testing was performed using Microsoft Excel and
GraphPad Prism software. N values and experimental replicates
are detailed in figure legends. ‘‘N’’ refers to independent experi-
ments or animals (mice or litters); ‘‘n’’ refers to technical replicates.
Graphs display means ± SEM unless otherwise stated. Statistical
testing was based on t tests or one-way ANOVA with specific post-
hoc comparison tests as detailed in figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and two figures and can be found with this article on-
line at https://doi.org/10.1016/j.stemcr.2019.01.007.
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